01.28.15
Ash Stevens, Inc. has received FDA approval for its facility in Riverview, MI for the manufacture of Amotosalen, the API in Cerus Corp.'s (CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).
"We are proud to be Cerus Corp.'s outsourcing partner for the development and manufacture of this important API. We have had a collaborative and highly productive relationship with Cerus for many years and we are excited to help provide this innovative product to patients," said Dr. Stephen Munk president and chief executive officer of Ash Stevens.
"We are proud to be Cerus Corp.'s outsourcing partner for the development and manufacture of this important API. We have had a collaborative and highly productive relationship with Cerus for many years and we are excited to help provide this innovative product to patients," said Dr. Stephen Munk president and chief executive officer of Ash Stevens.